GlassScriptPhysician profile
Deborah J Villa
NPI 1194726042
$1,577.44
in general payments reported to CMS, 2019-2025
16 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $84.53 · 2021: $213 · 2022: $321 · 2023: $443 · 2024: $86.37 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $722.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Secura Bio, INC. | $745.84 | 2021-2025 | Copiktra |
| E.R. Squibb & Sons, L.L.C. | $161.04 | 2019-2023 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $154.40 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.87 | 2022 | |
| Abbvie INC. | $87.04 | 2023-2024 | Venclexta |
| Alexion Pharmaceuticals, INC. | $74.70 | 2021 | |
| Medtronic, INC. | $43.40 | 2022-2024 | Synchromedii |
| Janssen Biotech, INC. | $42.58 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $35.19 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.75 | 2022 | |
| Amgen INC. | $24.33 | 2022 | |
| Dendreon Pharmaceuticals LLC | $20.57 | 2020 | |
| Exelixis INC. | $19.29 | 2019 | |
| Pfizer INC. | $17.72 | 2024 | |
| Emd Serono, INC. | $15.24 | 2023 | Tepmetko |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $14.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Villa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.